Is Aptorum Group Ltd (APM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 51.5% / 30% | 13.4% / 30% | 0.1% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 51.5% / 33% | 13.4% / 33% | 0.1% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 20.8% / 33% | 5.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 51.5% / 33% | 13.4% / 33% | 0.1% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 20.8% / 33% | 5.4% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -10.8% | |
| Return on Assets (ROA) | -6.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$1M |
| Free Cash Flow | -$1M |
| Total Debt | $3M |
| Debt-to-Equity | 25.0 |
| Current Ratio | 0.8 |
| Total Assets | $16M |
Price & Trading
| Last Close | $1.02 |
| 50-Day MA | $0.88 |
| 200-Day MA | $1.33 |
| Avg Volume | 53K |
|
52-Week Range
$0.65
| |
About Aptorum Group Ltd (APM)
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Aptorum Group Ltd (APM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aptorum Group Ltd is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Aptorum Group Ltd's debt ratio?
Aptorum Group Ltd's debt ratio is 51.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 20.8%.
What are Aptorum Group Ltd's key financial metrics?
Aptorum Group Ltd has a market capitalization of $8M. Return on equity stands at -10.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.